All Releases
 |
Trius Announces Issuance of Tedizolid Patent in China
Feb 16, 2012
|
9.3 KB |
|
| |
SAN DIEGO, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China (PRC) that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to...
|
|
Trius to Present at the BIO CEO & Investor Conference
Feb 7, 2012
|
7.3 KB |
|
| |
SAN DIEGO, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Monday, February 13 at 3:30 p.m. (EST) at the 14th Annual BIO CEO & Investor Conference. The presentation will take place ...
|
|
Trius Therapeutics, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares for Common Stock Offering
Jan 30, 2012
|
10.3 KB |
|
| |
SAN DIEGO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full their option to purchase an additional 1,290,000 shares of common stock. With the sale of the additional shares at a price to the public of $5.25 per ...
|
|
Trius Therapeutics, Inc. Prices Public Offering of Common Stock
Jan 26, 2012
|
11.1 KB |
|
| |
SAN DIEGO, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 8,600,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to Trius from this offering are expected to be approximately $45.2 million, before deducting underw...
|
|
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Jan 25, 2012
|
10.7 KB |
|
| |
SAN DIEGO, Jan. 25, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup and Piper Jaffray & Co. are acting as joint book-running managers. The offering is subject to market conditions, and there can be no assurance ...
|
|
Trius Earns $5 Million Milestone Payment From Bayer for Successful Completion of First Phase 3 Trial of Tedizolid
Jan 23, 2012
|
10.2 KB |
|
| |
SAN DIEGO, Jan. 23, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that it has earned a $5 million milestone payment from Bayer Healthcare for the achievement of all efficacy and safety objectives in the TR701-112 Phase 3 pivotal study which tested the oral dosage form of tedizolid phosphate versus the comparator li...
|
|
Trius Reports Positive Results From First Phase 3 Trial of Tedizolid in Acute Bacterial Skin and Skin Structure Infections
Dec 19, 2011
|
13.1 KB |
|
| |
Tedizolid over 6 days of therapy achieved all primary and secondary efficacy endpoints versus 10 days of linezolidTedizolid demonstrated a lower incidence of adverse events
SAN DIEGO, Dec. 19, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that tedizolid phosphate met the primary objective of non-inferiority fo...
|
|
Trius to Host Analyst and Investor Day in New York
Nov 28, 2011
|
8.0 KB |
|
| |
SAN DIEGO, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will host an analyst and investor day on Thursday, December 1 at 10:00 a.m. Eastern at the Millennium Broadway Hotel. In addition to a tedizolid phosphate overview by Trius management, the program will feature guest presentations by ...
|
|
Trius to Present at Piper Jaffray Healthcare Conference
Nov 22, 2011
|
6.9 KB |
|
| |
SAN DIEGO, Nov. 22, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday, November 29 at 10:30 a.m. at the 23rd Annual Piper Jaffray Healthcare Conference. The presentation will take pla...
|
|
Trius Therapeutics Reports 2011 Third Quarter Financial Results
Nov 10, 2011
|
19.4 KB |
|
| |
SAN DIEGO, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today its financial results for the third quarter ended September 30, 2011 and provided an update on recent ...
|
|
Trius to Present at Credit Suisse Healthcare Conference
Nov 7, 2011
|
6.8 KB |
|
| |
SAN DIEGO, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, November 11 at 7:30 a.m. at the 20th Annual Credit Suisse Healthcare Conference. The presentation will take place ...
|
|
Trius Therapeutics to Present at October 2011 Investor Conferences
Oct 17, 2011
|
7.1 KB |
|
| |
SAN DIEGO, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will present at the following investor conferences:
Newsmakers in the Biotech Industry at 9:00 a.m. Eastern Time on Friday, October 21st at the Millennium Broadway Hotel in New York.
BIO Investor Forum at 10:00 a.m. Pacific...
|
|
Trius Initiates Second Phase 3 Trial in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Sep 29, 2011
|
10.2 KB |
|
| |
SAN DIEGO, Sept. 29, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the dosing of the first patient in a second global Phase 3 pivotal trial in acute bacterial skin and skin structure infections (ABSSSI). The trial, designated TR701-113, is testing tedizolid phosphate (formerly known as torezolid phosphate) administ...
|
|
Trius to Present at the JMP Securities Healthcare Conference
Sep 23, 2011
|
7.3 KB |
|
| |
SAN DIEGO, Sept. 23, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday September 27 at 10:30 a.m. at the 6th Annual JMP Securities Healthcare Conference. The presentation will take pl...
|
|
Trius Announces Completion of Enrollment in Phase 3 Trial
Sep 15, 2011
|
9.1 KB |
|
| |
SAN DIEGO, Sept. 15, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has completed the enrollment of the first of two planned Phase 3 trials of tedizolid phosphate (formerly known as torezolid phosphate) in the study of acute bacterial skin and skin structure infections (ABSSSI). The pivotal Phase 3 ...
|
|
Trius Therapeutics to Present Data From Antibiotic Drug Development Programs at ICAAC
Sep 14, 2011
|
12.2 KB |
|
| |
SAN DIEGO, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate tedizolid phosphate (formerly known as torezolid phosphate and TR-701), will be presented in poster and slide presentations at the ...
|
|
Trius Therapeutics Reports 2011 Second Quarter Financial Results
Aug 11, 2011
|
17.6 KB |
|
| |
SAN DIEGO, Aug. 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today its financial results for the second quarter ended June 30, 2011 and provided an update on recent key ...
|
|
Trius to Present at Canaccord Genuity Growth Conference
Aug 5, 2011
|
6.8 KB |
|
| |
SAN DIEGO, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday, August 9 at 5:00 p.m. at the 2011 Canaccord Genuity Growth Conference. The presentation will take place in Boston...
|
|
Trius Therapeutics Obtains Special Protocol Assessment With FDA for Second Phase 3 Study of Torezolid Phosphate
Aug 5, 2011
|
8.3 KB |
|
| |
SAN DIEGO, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its second planned Phase 3 study for the intravenous and oral dosage forms of torezolid phos...
|
|
Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia-Pacific and Emerging Markets
Jul 27, 2011
|
11.4 KB |
|
| |
SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius' lead Phase 3 antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East,...
|
|
|
